President-elect Donald Trump’s threat to "tariff Denmark at a very high level” unless the nation cedes Greenland to the United States could create new challenges for Novo Nordisk, the Danish drugmaker behind the blockbuster weight-loss and diabetes drugs Ozempic and Wegovy. A tariff on Danish products would likely drive Novo Nordisk to raise drug prices in the United States, a key market for the company, according to an expert. Novo Nordisk told Inside Health Policy that it is closely...